there seems to be some heavy resistance around these level with a lot of potential upside.

China; GSK linked guy sentenced

I think today may have been the day to buy!

Or maybe not!

Exclusive: GlaxoSmithKline faces fresh drug bribery claims in Syria

GSK on Syria latest.

I've had a small long here @1,386.00 in the hope that the bottom is in (for now).

You may be right. I did the same last week.
GSK in NY does not seem to be doing much. Been the same for quite a few
days now. Here.

Thanks - I've got it on my NYSE monitor - albeit 15 minutes delayed.

Aug 15: Credit Suisse: Undderperform - Tp: 1475p

Glaxo Receives US Approval For Asthma Treatment Arnuity Ellipta

LONDON (Alliance News) - GlaxoSmithKline PLC said late Wednesday the US Food and Drug Administration has approved its Arnuity Ellipta treatment for asthma in patients aged 12 years and older.

Arnuity is not indicated for the relief of acute bronchospasm, Glaxo said. It was approved for 100 microgram and 200 microgram doses, and is administered daily via the Ellipta dry powder inhaler, which is also used for a range of other respiratory medicines in Glaxo's portfolio.

"The approval of Arnuity Ellipta is an important development for GSK and our expanding respiratory portfolio. It is the first asthma treatment from our new portfolio to have gained approval in the US and enables us to begin expanding the range of medicines that we offer to physicians and appropriate patients," said Darrell Baker, senior vice president and head of Glaxo's Global Respiratory Franchise in a statement.

A bit of a steal at these levels I reckon.

Aug 21: Deutsche; Hold - TP: 1500p

Just been limited out of half +55p

Just bought them back 11p cheaper.

Triumeq US Approval

London, UK, 22 August, 2014 - ViiV Healthcare announced today that the US Food and Drug Administration (FDA) has approved Triumeq® (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg) tablets for the treatment of HIV-1 infection.1 Triumeq is ViiV Healthcare's first dolutegravir-based fixed-dose combination, offering many people living with HIV the option of a single-pill regimen that combines the integrase strand transfer inhibitor (INSTI) dolutegravir, with the nucleoside reverse transcriptase inhibitors (NRTIs) abacavir and lamivudine.

more..

From 1365 intraday low on 8 August to 1462 today... the comeback kid.

Well done Midknight - I bought @1,386, sold half +55 and bought them back 11p lower.

So far, so good.

Ebola

Good find Midkinght - shaping up rather well!

Triumeq receives EU approval

GlaxoSmithKline plc (LSE:GSK) today announced that ViiV Healthcare Ltd (a global specialist HIV company with GlaxoSmithKline, Pfizer, Inc. and Shionogi Limited as shareholders) is issuing the following statement today:

ViiV Healthcare receives EU marketing authorisation for Triumeq® (dolutegravir/abacavir/lamivudine), a new once-daily single-pill regimen for the treatment of HIV

Once this area of noise is behind, hopefully a move to @1540 PDQ.